The subgroup analysis by control condition categories showed a significant disulfiram superiority as compared to naltrexone (g = .77, 95%CI = .52–1.02), acamprosate (g = .76, 95%CI = .04–1.48), and to the no disulfiram condition (g = .43, 95%CI = .17–.69) (Figure 6). Our meta-analysis showed that disulfiram was also more effective than topiramate, and no different from GHB, but as only one study could be included for each of two comparisons, our meta-analysis does not add valuable information to this question. Heterogeneity measures were I2 = 81% for the acamprosate controlled studies; I2 = 26% for the naltrexone controlled studies; and I2 = 44% for the no disulfiram controlled studies.
